Erratum: LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone (American Journal of Hypertension (2015) 28:12 (1409-1417) DOI: 10.1093/ajh/hpv015);LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone

American Journal of Hypertension

Volumn 28, Issue 12, 2015, Pages 1409-1417

  Kusaka, Hiroaki ^a   Sueta, Daisuke ^a   Koibuchi, Nobutaka ^a   Hasegawa, Yu ^a   Nakagawa, Takashi ^a   Lin, Bowen ^a   Ogawa, Hisao ^a   Kim Mitsuyama, Shokei ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

angiotensin; blood pressure; cardiovascular protection; dual inhibition; hypertension; neprilysin

Indexed keywords

ALDOSTERONE; CHOLESTEROL; CREATININE; CYCLIC GMP; GLUCOSE; INSULIN; RENIN; SACUBITRIL PLUS VALSARTAN; TRIACYLGLYCEROL; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE; SODIUM INTAKE; TETRAZOLE DERIVATIVE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL WALL THICKENING; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL WALL; CARDITIS; CHOLESTEROL BLOOD LEVEL; CIRCADIAN RHYTHM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIURESIS; DRUG DOSE INCREASE; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HEART INJURY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE HYPERTROPHY; HIGH SODIUM INTAKE; HYPERTENSION; INSULIN BLOOD LEVEL; LOCOMOTION; MALE; METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; SODIUM BALANCE; SODIUM RESTRICTION; SODIUM URINE LEVEL; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TELEMETRY; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; CARDIAC MUSCLE; CARDIOMEGALY; DRUG EFFECTS; FIBROSIS; HEART; INFLAMMATION; PATHOLOGY; PRECLINICAL STUDY; RANDOMIZATION; SODIUM INTAKE; URINE; VASCULAR ENDOTHELIUM; VASCULAR REMODELING;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CIRCADIAN RHYTHM; CYCLIC GMP; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; FIBROSIS; HEART; HYPERTENSION; INFLAMMATION; MALE; MYOCARDIUM; NEPRILYSIN; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS, INBRED SHR; SODIUM, DIETARY; TETRAZOLES; VALSARTAN; VASCULAR REMODELING;

EID: 84947606701     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpab149     Document Type: Erratum

References (24)

1. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003; 41:383-389.
2. von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC Jr, Krum H. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013; 6:594-605.
3. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992; 10:607-613.
4. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet 1998; 351:1657-1658.
5. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: theOmapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103-111.
6. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004; 164:910-913.
7. Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, Ballaron SJ, Cox BF, Trevillyan JM, Reinhart GA, von Geldern TW. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008; 153:947-955.
8. Toh S, Reichman ME, Houstoun M, Ross Southworth M, Ding X, Hernandez AF, Levenson M, Li L, McCloskey C, Shoaibi A, Wu E, Zornberg G, Hennessy S. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012; 172:1582-1589.
9. Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, Cheruvu M, Olsufka R, Sandvik ER, Lane CE, Budman J, Hill CM, Klein U, Hegde SS. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol 2011; 57:495-504.
10. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50:401-414.
11. Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther 2013; 94:445-448.
12. Gardner DG, Chen S, Glenn DJ, Grigsby CL. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007; 49:419-426.
13. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-328.
14. Pandey KN. Biology of natriuretic peptides and their receptors. Peptides 2005; 26:901-932.
15. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375:1255-1266.
16. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993-1004.
17. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi V, Solomon SD, Swedberg K, Zile MR, Andersen K, Arango JL, Arnold M, Belohlavek J, Bohm M, Boytsov SA, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez EA, Gonzalez-Medina A, Hagege AA, Huang J, Katova TM, Kiatchoosakun S, Kim KS, Kozan O, Llamas EA, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires F, Refsgaard J, Rosenthal A, Senni M, Sibulo AS, Cardoso JS, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131:54-61.
18. von Lueder TG, Wang BH, Kompa AR, Huang L, Webb R, Jordaan P, Atar D, Krum H. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 2015; 8:71-78.
19. Sueta D, Kataoka K, Koibuchi N, Toyama K, Uekawa K, Katayama T, Mingjie M, Nakagawa T, Waki H, Maeda M, Yasuda O, Matsui K, Ogawa H, Kim-Mitsuyama S. Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome-the critical role of angiotensin II. J Am Heart Assoc 2013; 2:e000035.
20. Sueta D, Nakamura T, Dong YF, Kataoka K, Koibuchi N, Yamamoto E, Toyama K, Yasuda O, Ogawa H, Kim-Mitsuyama S. Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. Am J Hypertens 2012; 25:704-710.
21. Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, Kraigher-Krainer E, Shah AM, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail 2014; 7:953-959.
22. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395.
23. Sueta D, Koibuchi N, Hasegawa Y, Toyama K, Uekawa K, Katayama T, Ma M, Nakagawa T, Ogawa H, Kim-Mitsuyama S. Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity. Am J Hypertens 2014; 27:1464-1471.
24. Takaya K, Ogawa Y, Hiraoka J, Hosoda K, Yamori Y, Nakao K, Koletsky RJ. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 1996; 14:130-131